Adlai Nortye (ANL) Leases (2023 - 2025)

Adlai Nortye (ANL) reported Leases of $636000.0 for Q2 2025, down 6.19% year-over-year from $678000.0 in Q2 2024, and down 33.89% on a QoQ basis from $962000.0 in Q4 2024.

Adlai Nortye (ANL) has 3 years of Leases data on file, last reported at $636000.0 in Q2 2025.

  • Quarterly Leases fell 6.19% year-over-year to $636000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $636000.0 (down 6.19% YoY) and the FY2024 annual result came in at $962000.0, down 16.64% from the prior year.
  • Leases retreated to $636000.0 in Q2 2025 per ANL's latest filing, from $962000.0 in the prior quarter.
  • Across five years, Leases topped out at $1.2 million in Q4 2023 and bottomed at $636000.0 in Q2 2025.
  • The 3-year median for Leases is $820000.0 (2024), against an average of $857500.0.
  • The widest annual swing landed in 2024, when Leases fell 16.64%; it then fell 6.19% in 2025.
  • Tracing ANL's Leases over 3 years: stood at $1.2 million in 2023, then declined by 16.64% to $962000.0 in 2024, then slumped by 33.89% to $636000.0 in 2025.
  • Per Business Quant, the three latest ANL Leases figures stand at $636000.0 (Q2 2025), $962000.0 (Q4 2024), and $678000.0 (Q2 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Leases (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - 83,048.00
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - 61,822.50
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 285.20 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 1.69 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn -
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 189.30 Mn
10 Adlai Nortye 23,840.00 -8.03 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 636,000.00
Dec 31, 2024 962,000.00
Jun 30, 2024 678,000.00
Dec 31, 2023 1.15 Mn